IOVA

4.26

13.75% 0.515

Handel nachbörslich: 4.35 0.09 +2.11%

Iovance Biotherapeutics Inc (IOVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IOVA? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$3.745

Offen:

$3.8

24-Stunden-Volumen:

24.50M

Relative Volume:

1.90

Marktkapitalisierung:

$1.75B

Einnahmen:

$241.53M

Nettoeinkommen (Verlust:

$-389.92M

KGV:

-3.4634

EPS:

-1.23

Netto-Cashflow:

$-323.54M

1W Leistung:

+11.23%

1M Leistung:

+74.59%

6M Leistung:

+93.64%

1J Leistung:

+8.67%

1-Tages-Spanne:

$3.73

$4.28

1-Wochen-Bereich:

$3.50

$4.28

52-Wochen-Spanne:

$1.6385

$4.35

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Firmenname

Iovance Biotherapeutics Inc

Sektor

Healthcare (1106)

Branche

Biotechnology (621)

Telefon

(650) 260-7120

Adresse

825 INDUSTRIAL ROAD, SAN CARLOS

Mitarbeiter

975

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IOVA Iovance Biotherapeutics Inc	4.26	1.54B	241.53M	-389.92M	-323.54M	-1.23
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-15	Herabstufung	Goldman	Neutral → Sell
2025-05-16	Herabstufung	UBS	Buy → Neutral
2025-05-12	Herabstufung	Truist	Buy → Hold
2025-05-09	Herabstufung	Citizens JMP	Mkt Outperform → Mkt Perform
2024-10-24	Eingeleitet	UBS	Buy
2024-07-29	Herabstufung	Piper Sandler	Overweight → Neutral
2023-11-20	Eingeleitet	Goldman	Buy
2023-09-18	Bestätigt	Barclays	Overweight
2023-05-30	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-27	Fortgesetzt	Wells Fargo	Equal Weight
2023-01-27	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-09	Herabstufung	Goldman	Buy → Neutral
2022-10-31	Eingeleitet	Guggenheim	Neutral
2022-08-18	Fortgesetzt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Stifel	Hold → Buy
2021-12-07	Fortgesetzt	Cowen	Outperform
2021-06-10	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Herabstufung	Piper Sandler	Overweight → Neutral
2021-05-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Herabstufung	Stifel	Buy → Hold
2021-05-03	Eingeleitet	Truist	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2021-03-08	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-10-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-22	Eingeleitet	Mizuho	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-02-26	Bestätigt	Oppenheimer	Outperform
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-10-01	Eingeleitet	Stifel	Buy
2019-04-29	Eingeleitet	Piper Jaffray	Overweight
2019-02-28	Bestätigt	Chardan Capital Markets	Buy
2019-02-07	Eingeleitet	Robert W. Baird	Outperform
2018-12-31	Fortgesetzt	B. Riley FBR	Buy
2018-07-06	Bestätigt	Chardan Capital Markets	Buy
2018-04-10	Hochstufung	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Bestätigt	B. Riley FBR, Inc.	Neutral
2018-02-23	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Bestätigt	H.C. Wainwright	Buy
2017-11-01	Bestätigt	B. Riley FBR, Inc.	Buy

Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

Mar 04, 2026

RSU vesting boosts Iovance (NASDAQ: IOVA) CRO share holdings - Stock Titan

Mar 04, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher After Analyst Upgrade - MarketBeat

Mar 04, 2026

Iovance Biotherapeutics’ TIL Therapy Showcases Promising Results - StocksToTrade

Mar 04, 2026

Iovance Biotherapeutics: Short-Term Pain, Long-Term GainI'm Still Bullish After All These Years - Seeking Alpha

Mar 04, 2026

Iovance Biotherapeutics’ Stock Rallies After Promising Trial Data - timothysykes.com

Mar 04, 2026

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛

Mar 04, 2026

Mar 03, 2026

Citizens Upgrades Iovance Biotherapeutics (IOVA) - Nasdaq

Mar 03, 2026

Assessing Iovance Biotherapeutics (IOVA) Valuation After Amtagvi Momentum And New Fast Track Designation - Sahm

Mar 03, 2026

IOVA Receives Analyst Upgrade to Market Outperform by Citizens | - GuruFocus

Mar 03, 2026

Citizens Jmp Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to "Market Outperform" - MarketBeat

Mar 03, 2026

A Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts - Benzinga

Mar 03, 2026

This Unity Software Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday - Benzinga

Mar 03, 2026

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Up 24.8% in February - MarketBeat

Mar 03, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Gains Visibility Across The Nasdaq Index - Kalkine Media

Mar 03, 2026

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Mar 03, 2026

Mar 02, 2026

IOVA: AMTAGVI drives robust growth as pipeline advances toward major milestones in lung and sarcoma - TradingView

Mar 02, 2026

Mar 01, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 01, 2026

Feb 28, 2026

Iovance Lifileucel Progress Reshapes Growth Prospects Beyond Melanoma - Yahoo Finance

Feb 28, 2026

IOVA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026

Why Iovance Biotherapeutics (IOVA) Is Up 34.5% After Amtagvi-Fueled Revenue Jump And Lifileucel Fast Track - Sahm

Feb 28, 2026

Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold - MarketBeat

Feb 28, 2026

Feb 27, 2026